ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immunoglobulins, Intravenous

Also written as “NPB-01”, “TAK-881” and “IVIG”.

Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.

Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201783 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda203 open or runningphase 4since Apr 12, 2017Sep 8, 2005May 16, 2028phase 3 · NCT06076642
Grifolsits history only172 open or runningphase 4since Oct 24, 2011Sep 13, 2005Dec 31, 2027phase 3 · NCT07540221
Nihon Pharmaceuticalits history only80 open or runningphase 3since Jul 27, 2011Dec 11, 2008none ahead
Octapharmaits history only61 open or runningphase 3since Nov 11, 2009Nov 11, 2009Nov 2026phase 3 · NCT04640142
CSLits history only51 open or runningphase 3since Oct 12, 2011Oct 12, 2011May 6, 2029phase 2 · NCT07048262
Kedrionits history only53 open or runningphase 3since Apr 16, 2012Apr 16, 2012Dec 2026phase 3 · NCT07059000
Japan Blood Products Organizationits history only40 open or runningphase 3since Jun 8, 2006Jun 8, 2006none ahead
GC Biopharmaits history only31 open or runningphase 3since Jul 26, 2011Jul 26, 2011none ahead
Prothya Biosolutionsits history only30 open or runningphase 4since Aug 29, 2007Aug 29, 2007none ahead
Azidus Brasilits history only22 open or runningphase 3since Sep 19, 2023Sep 19, 2023Sep 2028phase 3 · NCT06150833

Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Sep 8, 2005.

  1. Jan 7, 2009Phase 3 study in DementiaNCT00818662 · 390 enrolled · United States, Canada
  2. Oct 8, 2010Phase 3 study in Primary Immunodeficiency DiseasesNCT01218438 · 86 enrolled · United States, Canada
  3. Aug 8, 2011Phase 3 study in Primary Immunodeficiency DiseasesNCT01412385 · 55 enrolled · Austria, Germany, Hungary and more
  4. Jan 20, 2012Phase 3 study in Alzheimer´s DiseaseNCT01524887 · 508 enrolled · United States, Australia, Belgium and more
  5. Nov 27, 2012Phase 3 study in Alzheimer´s DiseaseNCT01736579 · 6 enrolled · United States
  6. Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesNCT03116347 · 42 enrolled · Czechia, Denmark, France and more
  7. Apr 10, 2020Phase 3 study in Primary Immunodeficiency DiseasesNCT04346108 · 17 enrolled · Japan
  8. Aug 27, 2021Phase 1 study in Healthy VolunteersNCT05059977 · 24 enrolled · United States
  9. Jan 26, 2023Phase 3 study in Primary Immunodeficiency DiseasesNCT05755035 · 65 enrolled · United States, Czechia, Denmark and more
  10. Oct 4, 2023Phase 3 study in Primary Immunodeficiency DiseasesNCT06076642 · 53 enrolled · United States, Czechia, Denmark and more
  11. Dec 19, 2024Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06747351 · 59 planned · United States, Argentina, Czechia and more
  12. Mar 20, 2025Phase 1 study in Healthy VolunteersNCT06895967 · 30 enrolled · United States
  13. Apr 11, 2025Phase 1 study in Healthy VolunteersNCT06935266 · 64 enrolled · United States
  14. May 13, 2025Phase 3 study in Multiple MyelomaNCT06980480 · 183 planned · United States, Australia, Austria and more

Ahead

  1. May 16, 2028Primary completion: phase 3 study in Primary Immunodeficiency DiseasesNCT06076642
  2. Jun 25, 2028Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06747351
  3. Sep 11, 2028Primary completion: phase 3 study in Multiple MyelomaNCT06980480

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06980480Multiple Myeloma · United States, Australia, Austria and more3RecruitingSep 11, 2028183
NCT06935266Healthy Volunteers · United States1CompletedSep 27, 202564
NCT06895967Healthy Volunteers · United States1CompletedJul 24, 202530
NCT06747351Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Czechia and more3RecruitingJun 25, 202859
NCT06076642Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more3Active, not recruitingMay 16, 202853
NCT05755035Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more3CompletedJan 20, 202665
NCT05059977Healthy Volunteers · United States1CompletedApr 12, 202224
NCT04346108Primary Immunodeficiency Diseases · Japan3CompletedDec 22, 202117
NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more4CompletedJan 15, 202142
NCT01736579Alzheimer´s Disease · United States3TerminatedJun 4, 20136
NCT01524887Alzheimer´s Disease · United States, Australia, Belgium and more3TerminatedJul 16, 2013508
NCT01412385Primary Immunodeficiency Diseases · Austria, Germany, Hungary and more3CompletedMay 13, 201455
NCT01218438Primary Immunodeficiency Diseases · United States, Canada3CompletedMar 13, 201586
NCT00818662Dementia · United States, Canada3CompletedDec 10, 2012390
NCT00782106Primary Immunodeficiency Diseases · United States2CompletedNov 1, 200711
NCT00666263Multifocal Motor Neuropathy · United States, Canada, Denmark3CompletedAug 11, 201150
NCT00546871Primary Immunodeficiency Diseases · United States3CompletedJul 1, 200949
NCT00162006Purpura, Thrombocytopenic, Idiopathic · Czechia, Germany, Hungary and more2CompletedDec 3, 200328
NCT00161993Primary Immunodeficiency Diseases · Finland, Sweden2CompletedSep 24, 200324
NCT00157079Primary Immunodeficiency Diseases · United States3CompletedDec 16, 200361

How it is read

Names in the registry

  • “NPB-01”, 7 entries
  • “TAK-881”, 6 entries
  • “IVIG”, 6 entries
  • “Kedrion IVIG 10%”, 4 entries
  • “GB-0998”, 4 entries

Codes read as this program: TAK881, GC5107, GB0998.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.